TICKERNERD
Menu
BBIOBBIOHealthcare · Biotechnology

BBIO Stock Forecast: BridgeBio Pharma, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$80
−1.66% on the day

The 22 Wall Street analysts covering BridgeBio Pharma, Inc. hold a median 12-month price target of $108 — +35.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$15.6B
Ticker Nerd rank
68 / 100
Median analyst target
$108
Analysts covering
22
Total return, dividends reinvested
1W
−5.5%
1M
−5.0%
YTD
+4.4%
1Y
+56.0%
From 52W high
−11.4%
From 52W low
+68.9%
$47
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BridgeBio Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Value
92
Growth
91
Momentum
84
Quality
77
Accruals
47
Revisions
43
Issuance
13
Size
12

Volatility (93): The share price has been relatively steady.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26BBIOHigh $157Median $108Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says22 analysts
19 Buy3 Hold0 Sell
Low $80Median $108High $157

The green dot is the last close — the median target sits +35.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
12 Aug 2026Canaccord GenuityMaintainsBuy$104 → $106
12 Aug 2026JP MorganMaintainsOverweight$100 → $111
12 Aug 2026Truist SecuritiesMaintainsBuy$102 → $107
11 Aug 2026B of A SecuritiesMaintainsBuy$101 → $104
11 Aug 2026Morgan StanleyMaintainsOverweight$98 → $97
11 Aug 2026Piper SandlerMaintainsOverweight$111 → $115
11 Aug 2026TD CowenMaintainsBuy$95 → $110
11 Aug 2026Wells FargoMaintainsOverweight$98 → $102
16 July 2026CitigroupMaintainsNeutral$82 → $93
16 July 2026CitigroupMaintainsNeutral—
13 July 2026HC Wainwright & Co.MaintainsBuy$110 → $120
13 July 2026HC Wainwright & Co.MaintainsBuy—
16 June 2026MizuhoMaintainsOutperform—
3 June 2026Canaccord GenuityInitiatesBuy—
28 May 2026HC Wainwright & Co.ReiteratesBuy—
28 May 2026Morgan StanleyMaintainsOverweight—
26 May 2026Raymond JamesDowngradeMarket Perform—
19 May 2026CitigroupInitiatesNeutral—
11 May 2026HC Wainwright & Co.MaintainsBuy—
8 May 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

BridgeBio Pharma, Inc. (BBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.1×

Cheaper than 96% of US stocks

Price / sales
21.9×

Cheaper than 9% of US stocks

Price / book
−6.9×

Cheaper than 97% of US stocks

EV / EBITDA
−38.7×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
120.4%

Higher than 94% of US stocks

Earnings growth (YoY)
66.8%

Higher than 80% of US stocks

Gross margin
94.9%

Higher than 98% of US stocks

Operating margin
−43.9%

Higher than 17% of US stocks

Net margin
−97.0%

Higher than 6% of US stocks

Returns & dividend
Return on equity
34.9%

Higher than 90% of US stocks

Return on assets
−26.0%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BBIOBridgeBio Pharma, Inc.$15.6B
68
JAZZJazz Pharmaceuticals Plc$15.4B
100
EXELExelixis, Inc.$13.3B
98
BMRNBioMarin Pharmaceutical, Inc.$13.0B
59
CORTCorcept Therapeutics, Inc.$12.3B
78
ARWRArrowhead Pharmaceuticals, Inc.$12.1B
57
MDGLMadrigal Pharmaceuticals, Inc.$11.6B
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BridgeBio Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBIO news & analysis

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

The Motley Fool · 14 Aug 2026positive

BridgeBio Pharma's stock has risen 29% over the past three months. Sales of its heart drug nearly tripled year over year in the second quarter, and the company has additional medications in late-stage development that Wall Street views as having significant potential.

Why it matters — BridgeBio watchers would care because strong commercial growth from its heart drug and a promising late-stage pipeline appear to be driving heightened investor and analyst attention on the company.

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

GlobeNewsWire · 14 Aug 2026positive

BridgeBio Pharma announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The transaction is intended to help diversify the Company's shareholder base toward further high-quality, long-term ownership.

Why it matters — A BBIO watcher would care because the secondary offering broadens and stabilizes the institutional shareholder base, supporting the Company's evolution toward long-term, high-quality ownership.

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

GlobeNewsWire · 13 Aug 2026neutral

BridgeBio Pharma announced the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The company is not selling any shares and will not receive any of the offering's proceeds.

Why it matters — A BridgeBio watcher would care because an existing major shareholder is selling a sizable block of stock, which affects the supply of shares in the market even though BridgeBio receives no proceeds.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 11 Aug 2026neutral

BridgeBio Pharma announced that on August 8, 2026, its compensation committee approved inducement equity grants in restricted stock units to 56 new employees, covering an aggregate of 66,705 shares of common stock. The RSUs vest in quarterly installments starting August 16, 2027, subject to continued employment.

Why it matters — The grants indicate new employee hiring and equity issued outside standard shareholder-approved plans under Nasdaq Listing Rule 5635(c)(4), giving BBIO watchers visibility into recent headcount additions and potential share dilution.

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

Zacks Investment Research · 11 Aug 2026positive

BridgeBio reported a second-quarter loss that missed analyst estimates, while revenues beat expectations as sales of Attruby more than tripled, fueling growth and advancing the company's pipeline.

Why it matters — A BBIO watcher would care because the revenue beat and sharp jump in Attruby sales show strong commercial momentum that supports the company's continued growth and pipeline development.

FAQ

Frequently asked questions about BBIO stock

What is the BBIO stock price forecast for 2026-2027?

The 22 Wall Street analysts covering BridgeBio Pharma, Inc. have a median 12-month price target of $108, with estimates ranging from $80 to $157. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBIO stock a buy right now?

Of the 22 analysts covering BridgeBio Pharma, Inc., 19 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BridgeBio Pharma, Inc. 68 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBIO?

As at 15 Aug 2026, BridgeBio Pharma, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will BBIO stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +35.2% from the last close, and Ticker Nerd's factor model ranks BridgeBio Pharma, Inc. 68 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBIO stock forecast for 2030?

No analyst covering BridgeBio Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $157 over the next 12 months.

How has BBIO stock performed over the past year?

BridgeBio Pharma, Inc. returned +56.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BridgeBio Pharma, Inc. do?

BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for patients with genetic diseases and genetically driven cancers.

What is the latest news on BBIO?

The most recent item we track (The Motley Fool, 14 Aug 2026): "BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.". BridgeBio Pharma's stock has risen 29% over the past three months. Sales of its heart drug nearly tripled year over year in the second quarter, and the company has additional medications in late-stage development that Wall Street views as having significant potential.

Company

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for patients with genetic diseases and genetically driven cancers. The company concentrates on conditions with well-defined genetic causes, aiming to design targeted therapies that address the underlying molecular mechanisms driving these disorders. Its portfolio spans programs in areas such as rare inherited diseases, cardiology, neurology, and oncology, often targeting pathways where a clear genetic mutation or alteration has been identified. BridgeBio Pharma, Inc. partners with academic institutions, clinicians, and patient communities to identify high-impact targets and advance them through clinical development. The company also emphasizes rigorous scientific validation, reflected in a broad base of peer-reviewed research supporting its programs. Founded in the United States, BridgeBio Pharma, Inc. plays a significant role in the biopharmaceutical market by focusing on high unmet medical needs where precision medicine approaches can offer differentiated treatment options for patients with limited existing therapies.

CEO Dr. Neil Kumar Ph.D. · 999 employees · United States · https://bridgebio.com